Yasunori Ichiki
Kitakyushu, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment.
Journal: Journal of gastroenterology and hepatology
Published: May 21, 2025
Long-Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct-Acting Antivirals.
Journal: Journal of gastroenterology and hepatology
Published: November 06, 2024
Curative surgery for multiple hepatocellular carcinomas after lenvatinib plus transarterial chemoembolization: a case report.
Journal: Journal of surgical case reports
Published: June 13, 2023
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Journal: Alimentary pharmacology & therapeutics
Published: March 28, 2022
Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection.
Journal: Journal of gastroenterology and hepatology
Published: August 01, 2021
Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
Journal: Journal of gastroenterology and hepatology
Published: May 16, 2021
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Journal: Hepatology international
Published: February 26, 2021
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C.
Journal: Cancers
Published: July 23, 2020
Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
Journal: The Journal of infectious diseases
Published: April 29, 2020
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Journal: Internal medicine (Tokyo, Japan)
Published: January 12, 2018
The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Journal: Hepato-gastroenterology
Published: April 11, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026